Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022

Published: Apr-2014 | Format: PDF | GlobalData | Number of pages: 69 | Code: MRS - 24141

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Qutenza (capsaicin 8% patch) was developed by NeurogesX, and is the first and only prescription-strength capsaicin treatment. It was approved in Europe (where is it marketed under license to Astellas Pharma) in March 2009 for the treatment of peripheral NP in non-diabetic adults, both as a monotherapy and in combination with other products. In the US, Qutenza was approved by the FDA in November 2009 for the treatment of PHN. NeurogesX retained the full commercial rights to Qutenza in the US and worldwide (outside Europe).


  • Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Qutenza including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Qutenza for the top six countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Qutenza performance
  • Obtain sales forecast for Qutenza from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9

3 Disease Overview 11
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 13
3.1.1 Painful Diabetic Neuropathy 15
3.1.2 Postherpetic Neuralgia 16
3.1.3 Trigeminal Neuralgia 16
3.2 Etiology and Pathophysiology 17
3.2.1 Etiology 18
3.2.2 Pathophysiology 19

4 Disease Management 27
4.1 Diagnosis and Treatment Overview 27
4.1.1 Diagnosis 27
4.1.2 Treatment Overview and Guidelines 34

5 Competitive Assessment 44
5.1 Overview 44

6 Qutenza 49
6.1 Overview 49
6.2 Efficacy 50
6.3 Safety 51
6.4 SWOT Analysis 52
6.5 Forecast 53

7 Appendix 55
7.1 Bibliography 55
7.2 Abbreviations 59
7.3 Methodology 62
7.4 Forecasting Methodology 62
7.4.1 Diagnosed PDN, PHN, and TN Patients 62
7.4.2 Percent Drug-Treated Patients 63
7.4.3 General Pricing Assumptions 63
7.4.4 Individual Drug Assumptions 63
7.4.5 Generic Erosion 64
7.5 Physicians and Specialists Included in This Study 64
7.6 About the Authors 66
7.6.1 Author 66
7.6.2 Global Head of Healthcare 67
7.7 About GlobalData 68
7.8 Disclaimer 68

List of Tables

Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage 13
Table 2: Signs and Symptoms of NP 14
Table 3: Screening Tools for NP 28
Table 4: NP-Related Signs and Symptoms 30
Table 5: Treatment Guidelines for NP 35
Table 6: Recommended Drug Therapies for NP Conditions by Line of Therapy 41
Table 7: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012 43
Table 8: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013 46
Table 9: Select Products Used for NP Treatment, 2013 48
Table 10: Product Profile - Qutenza 50
Table 11: Qutenza SWOT Analysis, 2013 52
Table 12: Global Sales Forecasts ($m) for Qutenza, 2012-2022 54

List of Figures

Figure 1: Nociceptive Versus Neuropathic Pain 12
Figure 2: Etiology and Pathophysiology of NP 17
Figure 3: Pain Pathway - Somatosensory System 20
Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System 24
Figure 5: Pathophysiological Targets of NP Drugs 25
Figure 6: NeuSPIG Diagnostic Certainty Algorithm for NP 31
Figure 7: General Treatment Algorithm for NP 40

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3495 View Pricing